In this video, Fool health-care analyst David Williamson discusses Discovery Labs (NASDAQ: DSCO), as it struggles with yet another delay to its drug Surfaxin. Shares are down 15% on news that the FDA has requested Surfaxin product specifications and a new analytical chemistry method. It took the company an unbelievable five attempts to finally get this drug approved a year ago. David tells investors when they might expect the delays to end, and what the key things to watch with Discovery Labs will be in the meantime, as the company continues to lose out on sales and burn cash.